Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 233

1.

What is new in the treatment of Waldenstrom macroglobulinemia?

Castillo JJ, Treon SP.

Leukemia. 2019 Nov;33(11):2555-2562. doi: 10.1038/s41375-019-0592-8. Epub 2019 Oct 7. Review.

PMID:
31591468
2.

NCCN Guidelines Insights: Multiple Myeloma, Version 1.2020.

Kumar SK, Callander NS, Hillengass J, Liedtke M, Baljevic M, Campagnaro E, Castillo JJ, Chandler JC, Cornell RF, Costello C, Efebera Y, Faiman M, Garfall A, Godby K, Holmberg L, Htut M, Huff CA, Kang Y, Landgren O, Malek E, Martin T, Omel J, Raje N, Sborov D, Singhal S, Stockerl-Goldstein K, Tan C, Weber D, Johnson-Chilla A, Keller J, Kumar R.

J Natl Compr Canc Netw. 2019 Oct 1;17(10):1154-1165. doi: 10.6004/jnccn.2019.0049.

PMID:
31590151
3.

CXCR4 S338X clonality is an important determinant of ibrutinib outcomes in patients with Waldenström macroglobulinemia.

Gustine JN, Xu L, Tsakmaklis N, Demos MG, Kofides A, Chen JG, Liu X, Munshi M, Guerrera ML, Chan GG, Patterson CJ, Keezer A, Meid K, Dubeau T, Yang G, Hunter ZR, Treon SP, Castillo JJ.

Blood Adv. 2019 Oct 8;3(19):2800-2803. doi: 10.1182/bloodadvances.2019000635. No abstract available.

4.

Development of an Extensive Linkage Library for Characterization of Carbohydrates.

Galermo AG, Nandita E, Castillo JJ, Amicucci MJ, Lebrilla CB.

Anal Chem. 2019 Oct 15;91(20):13022-13031. doi: 10.1021/acs.analchem.9b03101. Epub 2019 Sep 30.

PMID:
31525948
5.

How we manage Bing-Neel syndrome.

Castillo JJ, Treon SP.

Br J Haematol. 2019 Nov;187(3):277-285. doi: 10.1111/bjh.16167. Epub 2019 Aug 20. Review.

PMID:
31430829
6.

Reply to F.D. Leonard.

Bustoros M, Sklavenitis-Pistofidis R, Castillo JJ, Treon SP, Ghobrial IM.

J Clin Oncol. 2019 Oct 10;37(29):2701-2702. doi: 10.1200/JCO.19.01708. Epub 2019 Aug 19. No abstract available.

PMID:
31424980
7.

HOLA! from Latin America to the myeloma world.

Castillo JJ.

Br J Haematol. 2019 Aug 4. doi: 10.1111/bjh.16137. [Epub ahead of print] No abstract available.

PMID:
31378927
8.

CXCR4 mutations affect presentation and outcomes in patients with Waldenström macroglobulinemia: A systematic review.

Castillo JJ, Moreno DF, Arbelaez MI, Hunter ZR, Treon SP.

Expert Rev Hematol. 2019 Oct;12(10):873-881. doi: 10.1080/17474086.2019.1649132. Epub 2019 Jul 30.

PMID:
31343930
9.

Hematogenous extramedullary relapse in multiple myeloma - a multicenter retrospective study in 127 patients.

Avivi I, Cohen YC, Suska A, Shragai T, Mikala G, Garderet L, Seny GM, Glickman S, Jayabalan DS, Niesvizky R, Gozzetti A, Wiśniewska-Piąty K, Waszczuk-Gajda A, Usnarska-Zubkiewicz L, Hus I, Guzicka R, Radocha J, Milunovic V, Davila J, Gentile M, Castillo JJ, Jurczyszyn A.

Am J Hematol. 2019 Oct;94(10):1132-1140. doi: 10.1002/ajh.25579. Epub 2019 Aug 13.

PMID:
31334859
10.

High Red Cell Distribution Width is an Adverse Predictive and Prognostic Factor in Patients With Diffuse Large B-Cell Lymphoma Treated With Chemoimmunotherapy.

Beltran BE, Paredes S, Castro D, Cotrina E, Sotomayor EM, Castillo JJ.

Clin Lymphoma Myeloma Leuk. 2019 Sep;19(9):e551-e557. doi: 10.1016/j.clml.2019.06.005. Epub 2019 Jun 15.

PMID:
31320254
11.

Prostate imaging reporting and data system correlation with Gleason score: Pathological aspects of magnetic resonance imaging findings.

Yokoo P, de Oliveira Salvador GL, Castillo JJAQ, Basso ACN, Amaral RSD, de Campos ROP, Barreto RAY, Orozco OFG, Cavalli AC, Zaparolli M.

Urologia. 2019 Nov;86(4):189-196. doi: 10.1177/0391560319858482. Epub 2019 Jul 14.

PMID:
31303145
12.

CXCR4 mutation subtypes impact response and survival outcomes in patients with Waldenström macroglobulinaemia treated with ibrutinib.

Castillo JJ, Xu L, Gustine JN, Keezer A, Meid K, Dubeau TE, Liu X, Demos MG, Kofides A, Tsakmaklis N, Chen JG, Munshi M, Guerrera ML, Chan GG, Patterson CJ, Yang G, Hunter ZR, Treon SP.

Br J Haematol. 2019 Nov;187(3):356-363. doi: 10.1111/bjh.16088. Epub 2019 Jul 3.

PMID:
31267520
13.

Lymphoplasmacytic Lymphoma and Marginal Zone Lymphoma.

Juárez-Salcedo LM, Castillo JJ.

Hematol Oncol Clin North Am. 2019 Aug;33(4):639-656. doi: 10.1016/j.hoc.2019.03.004. Epub 2019 Apr 30. Review.

PMID:
31229160
14.

Progression Risk Stratification of Asymptomatic Waldenström Macroglobulinemia.

Bustoros M, Sklavenitis-Pistofidis R, Kapoor P, Liu CJ, Kastritis E, Zanwar S, Fell G, Abeykoon JP, Hornburg K, Neuse CJ, Marinac CR, Liu D, Soiffer J, Gavriatopoulou M, Boehner C, Cappuccio JM, Dumke H, Reyes K, Soiffer RJ, Kyle RA, Treon SP, Castillo JJ, Dimopoulos MA, Ansell SM, Trippa L, Ghobrial IM.

J Clin Oncol. 2019 Jun 1;37(16):1403-1411. doi: 10.1200/JCO.19.00394. Epub 2019 Apr 16.

PMID:
30990729
15.

Ibrutinib for the treatment of Bing-Neel syndrome: a multicenter study.

Castillo JJ, Itchaki G, Paludo J, Varettoni M, Buske C, Eyre TA, Chavez JC, Shain KH, Issa S, Palomba ML, Pasvolsky O, Simpson D, Talaulikar D, Tam CS, Tedeschi A, Ansell SM, Nayak L, Treon SP.

Blood. 2019 Jan 24;133(4):299-305. doi: 10.1182/blood-2018-10-879593. Epub 2018 Dec 6.

PMID:
30523119
16.

Low risk of Pneumocystis jirovecii pneumonia and invasive aspergillosis in patients with Waldenström macroglobulinaemia on ibrutinib.

Cheng MP, Kusztos AE, Gustine JN, Dryden-Peterson SL, Dubeau TE, Woolley AE, Hammond SP, Baden LR, Treon SP, Castillo JJ, Issa NC.

Br J Haematol. 2019 May;185(4):788-790. doi: 10.1111/bjh.15627. Epub 2018 Nov 20. No abstract available.

PMID:
30460682
17.

Outcomes of secondary solid tumor malignancies among patients with myeloma: A population-based study.

Barth P, Castillo JJ, Olszewski AJ.

Cancer. 2019 Feb 15;125(4):550-558. doi: 10.1002/cncr.31853. Epub 2018 Nov 19.

PMID:
30452087
18.

Ibrutinib and Rituximab in Waldenström's Macroglobulinemia.

Olszewski AJ, Castillo JJ.

N Engl J Med. 2018 Nov 15;379(20):1973-4. doi: 10.1056/NEJMc1809505. No abstract available.

PMID:
30439672
19.

Long survival in patients with Waldenström macroglobulinaemia diagnosed at a young age.

Babwah A, Gustine J, Meid K, Dubeau T, Xu L, Yang G, Hunter ZR, Treon SP, Castillo JJ.

Br J Haematol. 2019 May;185(4):799-802. doi: 10.1111/bjh.15634. Epub 2018 Nov 8. No abstract available.

PMID:
30407630
20.

Insights into the genomic landscape of MYD88 wild-type Waldenström macroglobulinemia.

Hunter ZR, Xu L, Tsakmaklis N, Demos MG, Kofides A, Jimenez C, Chan GG, Chen J, Liu X, Munshi M, Gustine J, Meid K, Patterson CJ, Yang G, Dubeau T, Samur MK, Castillo JJ, Anderson KC, Munshi NC, Treon SP.

Blood Adv. 2018 Nov 13;2(21):2937-2946. doi: 10.1182/bloodadvances.2018022962.

21.

Bortezomib overcomes the negative impact of CXCR4 mutations on survival of Waldenstrom macroglobulinemia patients.

Sklavenitis-Pistofidis R, Capelletti M, Liu CJ, Reidy M, Zavidij O, Huynh D, Henrick P, Savell A, Reyes K, Rivotto B, Bustoros M, Perilla-Glen A, Trippa L, Castillo JJ, Treon SP, Ghobrial IM.

Blood. 2018 Dec 13;132(24):2608-2612. doi: 10.1182/blood-2018-07-863241. Epub 2018 Oct 26. No abstract available.

PMID:
30366921
22.

Profiling of circulating exosomal miRNAs in patients with Waldenström Macroglobulinemia.

Bouyssou JM, Liu CJ, Bustoros M, Sklavenitis-Pistofidis R, Aljawai Y, Manier S, Yosef A, Sacco A, Kokubun K, Tsukamoto S, Perilla Glen A, Huynh D, Castillo JJ, Treon SP, Leblond V, Hermine O, Roccaro AM, Ghobrial IM, Capelletti M.

PLoS One. 2018 Oct 4;13(10):e0204589. doi: 10.1371/journal.pone.0204589. eCollection 2018.

23.

Waldenström Macroglobulinemia: Lessons Learned from Basic and Clinical Research.

Castillo JJ, Kastritis E, Treon SP.

Hematol Oncol Clin North Am. 2018 Oct;32(5):xiii-xiv. doi: 10.1016/j.hoc.2018.07.001. No abstract available.

PMID:
30190026
24.

Monoclonal Antibodies for Waldenström Macroglobulinemia.

Dominguez A, Kastritis E, Castillo JJ.

Hematol Oncol Clin North Am. 2018 Oct;32(5):841-852. doi: 10.1016/j.hoc.2018.05.010. Epub 2018 Jul 21. Review.

PMID:
30190022
25.

Initial Evaluation of the Patient with Waldenström Macroglobulinemia.

Castillo JJ, Treon SP.

Hematol Oncol Clin North Am. 2018 Oct;32(5):811-820. doi: 10.1016/j.hoc.2018.05.008. Epub 2018 Jul 23. Review.

PMID:
30190019
26.

Genomic Landscape of Waldenström Macroglobulinemia.

Treon SP, Xu L, Liu X, Hunter ZR, Yang G, Castillo JJ.

Hematol Oncol Clin North Am. 2018 Oct;32(5):745-752. doi: 10.1016/j.hoc.2018.05.003. Epub 2018 Jul 25. Review.

PMID:
30190014
27.

TP53 mutations are associated with mutated MYD88 and CXCR4, and confer an adverse outcome in Waldenström macroglobulinaemia.

Gustine JN, Tsakmaklis N, Demos MG, Kofides A, Chen JG, Liu X, Munshi M, Guerrera ML, Chan GG, Patterson CJ, Meid K, Dubeau T, Yang G, Hunter ZR, Treon SP, Castillo JJ, Xu L.

Br J Haematol. 2019 Jan;184(2):242-245. doi: 10.1111/bjh.15560. Epub 2018 Sep 5.

PMID:
30183082
28.

Ibrutinib Monotherapy in Symptomatic, Treatment-Naïve Patients With Waldenström Macroglobulinemia.

Treon SP, Gustine J, Meid K, Yang G, Xu L, Liu X, Demos M, Kofides A, Tsakmaklis N, Chen JG, Munshi M, Chan G, Dubeau T, Raje N, Yee A, O'Donnell E, Hunter ZR, Castillo JJ.

J Clin Oncol. 2018 Sep 20;36(27):2755-2761. doi: 10.1200/JCO.2018.78.6426. Epub 2018 Jul 25.

PMID:
30044692
29.

Multiple myeloma in patients up to 30 years of age: a multicenter retrospective study of 52 cases.

Jurczyszyn A, Davila J, Kortüm KM, Jayabalan DS, Vij R, Fiala M, Milunovic V, Chim CS, Wiśniewska-Piąty K, Waszczuk-Gajda A, Crusoe E, Hajek R, Robak P, Raźny M, Zawirska D, Bittrich M, Nahi H, Liu J, Castillo JJ, Vesole DH.

Leuk Lymphoma. 2019 Feb;60(2):471-476. doi: 10.1080/10428194.2018.1480766. Epub 2018 Jul 22.

PMID:
30033832
30.

Clinical characteristics and treatment outcomes in IgE multiple myeloma: A case-control study.

Jurczyszyn A, Castillo JJ, Vesole DH, Liu J, Avivi I, Waszczuk-Gajda A, Lech-Maranda E, Gentile M, Mikala G, Guerrero-Garcia T, Suska A, Gertz MA.

Am J Hematol. 2018 Sep;93(9):E238-E241. doi: 10.1002/ajh.25209. Epub 2018 Aug 6. No abstract available.

31.

EBV-positive diffuse large B-cell lymphoma, not otherwise specified: 2018 update on diagnosis, risk-stratification and management.

Castillo JJ, Beltran BE, Miranda RN, Young KH, Chavez JC, Sotomayor EM.

Am J Hematol. 2018 Jul;93(7):953-962. doi: 10.1002/ajh.25112. Review.

32.

Secondary plasma cell leukemia: a multicenter retrospective study of 101 patients.

Jurczyszyn A, Castillo JJ, Avivi I, Czepiel J, Davila J, Vij R, Fiala MA, Gozzetti A, Grząśko N, Milunovic V, Hus I, Mądry K, Waszczuk-Gajda A, Usnarska-Zubkiewicz L, Dębski J, Atilla E, Beksac M, Mele G, Sawicki W, Jayabalan D, Charliński G, Gyula Szabo A, Hajek R, Delforge M, Kopacz A, Fantl D, Waage A, Crusoe E, Hungria V, Richardson P, Laubach J, Guerrero-Garcia T, Liu J, Vesole DH.

Leuk Lymphoma. 2019 Jan;60(1):118-123. doi: 10.1080/10428194.2018.1473574. Epub 2018 Jul 2.

PMID:
29965787
33.

The real world of Waldenström's macroglobulinaemia.

Treon SP, Castillo JJ.

Lancet Haematol. 2018 Jul;5(7):e275-e276. doi: 10.1016/S2352-3026(18)30091-7. No abstract available.

PMID:
29958567
34.

Viral lymphomagenesis: beyond the usual suspects.

Castillo JJ.

Br J Haematol. 2018 Sep;182(5):617-618. doi: 10.1111/bjh.15414. Epub 2018 May 29. No abstract available.

PMID:
29808932
35.

Impact of ibrutinib dose intensity on patient outcomes in previously treated Waldenström macroglobulinemia.

Castillo JJ, Gustine JN, Meid K, Dubeau TE, Xu L, Yang G, Hunter ZR, Advani R, Palomba L, Treon SP.

Haematologica. 2018 Oct;103(10):e466-e468. doi: 10.3324/haematol.2018.191999. Epub 2018 May 17. No abstract available.

36.

Spotting the elusive Siberian tiger: Complete response to ibrutinib in a patient with Waldenström Macroglobulinemia.

Castillo JJ, Dubeau T, Kofides A, Demos MG, Tsakmaklis N, Xu L, Hunter ZR, Treon SP.

Am J Hematol. 2018 May 14. doi: 10.1002/ajh.25142. [Epub ahead of print] No abstract available.

37.

Bio-inspired spiking neural network for nonlinear systems control.

Pérez J, Cabrera JA, Castillo JJ, Velasco JM.

Neural Netw. 2018 Aug;104:15-25. doi: 10.1016/j.neunet.2018.04.002. Epub 2018 Apr 12.

PMID:
29702424
38.

True, true unrelated? Coexistence of Waldenström macroglobulinemia and cardiac transthyretin amyloidosis.

Singh A, Geller HI, Alexander KM, Padera RF, Mitchell RN, Dorbala S, Castillo JJ, Falk RH.

Haematologica. 2018 Aug;103(8):e374-e376. doi: 10.3324/haematol.2018.190405. Epub 2018 Apr 19. No abstract available.

39.

Prospective Clinical Trial of Ixazomib, Dexamethasone, and Rituximab as Primary Therapy in Waldenström Macroglobulinemia.

Castillo JJ, Meid K, Gustine JN, Dubeau T, Severns P, Hunter ZR, Yang G, Xu L, Treon SP.

Clin Cancer Res. 2018 Jul 15;24(14):3247-3252. doi: 10.1158/1078-0432.CCR-18-0152. Epub 2018 Apr 16.

40.

MYD88 mutated and wild-type Waldenström's Macroglobulinemia: characterization of chromosome 6q gene losses and their mutual exclusivity with mutations in CXCR4.

Guerrera ML, Tsakmaklis N, Xu L, Yang G, Demos M, Kofides A, Chan GG, Manning RJ, Liu X, Chen JG, Munshi M, Patterson CJ, Castillo JJ, Dubeau T, Gustine J, Carrasco RD, Arcaini L, Varettoni M, Cazzola M, Treon SP, Hunter ZR.

Haematologica. 2018 Sep;103(9):e408-e411. doi: 10.3324/haematol.2018.190181. Epub 2018 Mar 29. No abstract available.

41.

A Procedure for Determining Tire-Road Friction Characteristics Using a Modification of the Magic Formula Based on Experimental Results.

Cabrera JA, Castillo JJ, Pérez J, Velasco JM, Guerra AJ, Hernández P.

Sensors (Basel). 2018 Mar 17;18(3). pii: E896. doi: 10.3390/s18030896.

42.

Low levels of von Willebrand markers associate with high serum IgM levels and improve with response to therapy, in patients with Waldenström macroglobulinaemia.

Castillo JJ, Gustine JN, Meid K, Dubeau T, Severns P, Xu L, Yang G, Hunter ZR, Treon SP.

Br J Haematol. 2019 Mar;184(6):1011-1014. doi: 10.1111/bjh.15200. Epub 2018 Mar 13. No abstract available.

PMID:
29532913
43.

Bortezomib plus EPOCH is effective as frontline treatment in patients with plasmablastic lymphoma.

Castillo JJ, Guerrero-Garcia T, Baldini F, Tchernonog E, Cartron G, Ninkovic S, Cwynarski K, Dierickx D, Tousseyn T, Lansigan F, Linnik Y, Mogollon R, Navarro JT, Olszewski AJ, Reagan JL, Fedele P, Gilbertson M, Grigoriadis G, Bibas M.

Br J Haematol. 2019 Feb;184(4):679-682. doi: 10.1111/bjh.15156. Epub 2018 Mar 12. No abstract available.

PMID:
29527667
44.

Author Correction: Sporadic nesting reveals long distance colonisation in the philopatric loggerhead sea turtle (Caretta caretta).

Carreras C, Pascual M, Tomás J, Marco A, Hochscheid S, Castillo JJ, Gozalbes P, Parga M, Piovano S, Cardona L.

Sci Rep. 2018 Mar 7;8(1):4338. doi: 10.1038/s41598-018-22718-7.

45.

BTKCys481Ser drives ibrutinib resistance via ERK1/2 and protects BTKwild-type MYD88-mutated cells by a paracrine mechanism.

Chen JG, Liu X, Munshi M, Xu L, Tsakmaklis N, Demos MG, Kofides A, Guerrera ML, Chan GG, Patterson CJ, Meid K, Gustine J, Dubeau T, Severns P, Castillo JJ, Hunter ZR, Wang J, Buhrlage SJ, Gray NS, Treon SP, Yang G.

Blood. 2018 May 3;131(18):2047-2059. doi: 10.1182/blood-2017-10-811752. Epub 2018 Mar 1.

PMID:
29496671
46.

The neutrophil-lymphocyte ratio is prognostic in patients with early stage aggressive peripheral T cell lymphoma.

Beltran BE, Castro D, De La Cruz-Vargas JA, Cotrina E, Gallo A, Sotomayor EM, Castillo JJ.

Br J Haematol. 2019 Feb;184(4):650-653. doi: 10.1111/bjh.15141. Epub 2018 Feb 26. No abstract available.

PMID:
29479670
47.

The impact of the neutrophil:lymphocyte ratio in response and survival of patients with de novo diffuse large B-cell lymphoma.

Beltrán BE, Paredes S, Cotrina E, Sotomayor EM, Castillo JJ.

Leuk Res. 2018 Apr;67:82-85. doi: 10.1016/j.leukres.2018.02.011. Epub 2018 Feb 19.

PMID:
29477024
48.

Ibrutinib withdrawal symptoms in patients with Waldenström macroglobulinemia.

Castillo JJ, Gustine JN, Meid K, Dubeau T, Severns P, Treon SP.

Haematologica. 2018 Jul;103(7):e307-e310. doi: 10.3324/haematol.2017.186908. Epub 2018 Feb 22. No abstract available.

49.

Response and survival for primary therapy combination regimens and maintenance rituximab in Waldenström macroglobulinaemia.

Castillo JJ, Gustine JN, Meid K, Dubeau TE, Severns P, Xu L, Yang G, Hunter ZR, Treon SP.

Br J Haematol. 2018 Apr;181(1):77-85. doi: 10.1111/bjh.15148. Epub 2018 Feb 22.

PMID:
29468652
50.

Ixazomib-induced cutaneous necrotizing vasculitis.

Alloo A, Khosravi H, Granter SR, Jadeja SM, Richardson PG, Castillo JJ, LeBoeuf NR.

Support Care Cancer. 2018 Jul;26(7):2247-2250. doi: 10.1007/s00520-018-4052-1. Epub 2018 Feb 1.

PMID:
29392482

Supplemental Content

Loading ...
Support Center